A Discrete Choice Experiment analysis to understand Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States

被引：0
|
作者：
Faiman, Beth [1 ]
Le, Hoa [2 ]
Laurent, Julie [3 ]
Patel, Saurabh [2 ]
Paner-Straseviciute, Agne [2 ]
Zhang, Xinke [4 ]
Mikhael, Joseph [5 ]
机构：
[1] Cleveland Clin, Cleveland, OH USA
[2] Johnson & Johnson Innovat Med, Raritan, NJ USA
[3] Caren Part EvidentIQ, Munich, Germany
[4] Janssen Sci Affairs, Baltimore, MD USA
[5] City Hope Natl Med Ctr, Duarte, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-400
引用
收藏
页码：S265 / S265
页数：1
相关论文
共 50 条
  • [31] Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Stiff, Patrick J.
    Ibrahim, Emad
    Vallurupalli, Anusha
    Cull, Elizabeth H.
    Green, Damian J.
    Oliver, Kate
    Longcor, Jarrod
    BLOOD, 2019, 134
  • [32] HEALTH RESOURCE UTILIZATION (HRU) AND COSTS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE UNITED STATES (US): A SYSTEMATIC LITERATURE REVIEW
    Hansen, D. K.
    Hasegawa, K.
    Itani, T.
    Giordana, M.
    Granados, E.
    Rosado, M. B.
    Chan, R. J.
    Kostic, A.
    Zannat, N. E.
    Lakzadeh, P.
    Mateos, M., V
    VALUE IN HEALTH, 2024, 27 (12)
  • [33] Treatment preferences of patients with relapsing multiple sclerosis: a discrete choice experiment
    Scherz, T.
    Boyanova, N.
    Brooks, A.
    Chua, G. N.
    Beyer, A.
    Levitan, B.
    Hennessy, B.
    Tervonen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 622 - 622
  • [34] Alignment of preferences in the treatment of multiple myeloma - a discrete choice experiment of patient, carer, physician, and nurse preferences
    Fifer, Simon J.
    Ho, Kerrie-Anne
    Lybrand, Sean
    Axford, Laurie J.
    Roach, Steve
    BMC CANCER, 2020, 20 (01)
  • [35] Alignment of preferences in the treatment of multiple myeloma – a discrete choice experiment of patient, carer, physician, and nurse preferences
    Simon J. Fifer
    Kerrie-Anne Ho
    Sean Lybrand
    Laurie J. Axford
    Steve Roach
    BMC Cancer, 20
  • [36] Predictors of Second-Line Treatment Choice with Triplet Therapy in Routine Care Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Romanus, Dorothy
    Jhaveri, Mehul
    Labotka, Richard
    Henk, Henry
    Seal, Brian
    BLOOD, 2015, 126 (23)
  • [37] Patient Characteristics, Treatment Patterns and Outcomes Among Relapsed/Refractory Multiple Myeloma (RRMM) Patients in Japan
    Jun, Gyungjin
    Luptakova, Katarina
    Koizumi, Hiroo
    Iwasaki, Kosuke
    Hiroi, Shinzo
    Soeda, Junpei
    BLOOD, 2016, 128 (22)
  • [38] Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Lonial, Sagar
    Mark, Tomer M.
    Krishnan, Amrita Y.
    Stockerl-Goldstein, Keith E.
    Usmani, Saad Z.
    Londhe, Anil
    Etheredge, Delores
    Fleming, Sarah
    Liu, Baolian
    Ukropec, Jon
    Lin, Thomas S.
    Jagannath, Sundar
    Nooka, Ajay K.
    CANCER, 2018, 124 (22) : 4342 - 4349
  • [39] Treatment Patterns in Patients (pts) with Refractory/Relapsed Multiple Myeloma (RRMM) in Germany between 2016 and 2018
    Merz, Maximilian
    Patel, Vishal
    Kutikova, Lucie
    Lebioda, Andrea
    Schoehl, Martina
    Kellermann, Lenka
    Goldschmidt, Hartmut
    BLOOD, 2019, 134
  • [40] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    HAEMATOLOGICA, 2017, 102 : 137 - 137
12345